title: Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx.
abstract: Therapeutic options for recurrent carcinoma of the upper aérodigestive tract (UADT) are limited. The prognosis of these tumours remains poor with significant rate of recurrence and a lower median survival time. Photodynamic therapy (PDT) is a relatively new therapeutic alternative which combines the use of a photosensitising agent and light to induce a cytotoxic effect on the tissues. This is a retrospective single-centre study carried out in patients with a recurrence of an oral cavity or oropharyngeal carcinoma or a second appearance of tumour in a previously irradiated area. There were no metastases in lymph nodes or other organs. Laser treatment was carried out 96 h after temoporfin (Foscan(®)) injection. In our series we had 14 cases with a complete response, 1 partial response. Overall survival at 1 year was 72 % and 36 % at 5 years. Disease-specific survival at 1 year was 82 % and 45 % at 5 years. Recurrence-free survival at 1 year was 52 % and 34 % at 5 years. Side effects mainly described are pain in the area of illumination, well controlled. PDT with Foscan(®) gives useful results in terms of survival and improvement in quality of life with few adverse events or severe complications. The fact that it has low toxicity and that treatment sessions can be repeated mean it should be considered in the therapeutic armamentarium for recurrent carcinoma of the UADT.
authors.affiliation: ENT Department, Hospices Civils de Lyon, Centre hospitalier Lyon Sud, Pierre-Bénite Cedex, France. mickael.durbec@hotmail.fr
authors.forename: M
authors.initials: M
authors.lastname: Durbec
authors.forename: A
authors.initials: A
authors.lastname: Cosmidis
authors.forename: C
authors.initials: C
authors.lastname: Fuchsmann
authors.forename: A
authors.initials: A
authors.lastname: Ramade
authors.forename: P
authors.initials: P
authors.lastname: Céruse
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006414:Hematoporphyrin Photoradiation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008652:Mesoporphyrins / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D008652:Mesoporphyrins; C072269:temoporfin